Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. - Área de Salud Badajoz

Ir al contenido principal

Av. de Huelva, 8. 06005 Badajoz

info@areasaludbadajoz.com

info@areasaludbadajoz.com

Guía telefónica
Área de Salud

Inicio Repositorio Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.

2019/03

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.

Autores/as:

Manso L, Moreno Antón F, Izarzugaza Perón Y, Delgado Mingorance JI, Borrega García P, Echarri González MJ, Martínez-Jañez N, López-González A, Olier Garate C, Ballesteros García A, Chacón López-Muñíz I, Ciruelos Gil E, García-Sáenz JA, Paz-Ares L

Servicio:

Oncologia radiorerápica.-Complejo Hospitalario Universitario de Badajoz

Tipo:

Artículo

Materia:

{«label»:»Resumen PubMed»,»link»:»https://www.ncbi.nlm.nih.gov/pubmed/30734437″}